JCR To Be First To Produce Local Biotech Generic In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's JCR Pharmaceuticals plans to make its entry into the mass-produced biotech generic sector in Japan with an erythropoietin protein-based treatment for anemia due to reduced kidney function. JCR said it expects to get government clearance for its generic at the beginning of next year and then produce it in a special factory it plans to construct by next summer. The JCR drug would be only the second bioengineered generic to be approved for sale in the country, the first being a human growth hormone that Sandoz imports from Australia. JCR plans to co-market the drug with Kissei Pharmaceutical. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.